References
- Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infec. Dis.44, 1289–1297 (2007).
- Denning DW. Invasive aspergillosis. Clin. Infect. Dis.26, 781–805 (1998).
- Pfaller M, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev.20, 133–163 (2007).
- Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.34, 7408–7415 (2002).
- Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36, 630–670 (2003).
- Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
- Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med.340, 764–771 (1999).
- Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis.31, 1155–1163 (2000).
- Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother.45, 3487–3496 (2001).
- Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol.103, 205–212 (1998).
- Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis.27, 1406–1412 (1998).
- Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother.45, 922–926 (2001).
- Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother.28(Suppl B.), 73–82 (1991).
- Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch. Intern. Med.155, 1093–1098 (1995).
- Tollemar J, Andersson S, Ringdén O, Tydén G. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses35, 215–220 (1992).
- Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericn B: clinical experience and perspectives. Expert Rev. Anti Infect. Ther.3, 167–180 (2005).
- Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med. Mycol.44, S315–S318 (2006).
- Annaissie EJ. Trial design for mold-active agents: time to break the mold – aspergillosis in neutropenic adults. Clin. Infect. Dis.44, 1298–1306 (2007).
- De Pauw BE, Patterson TE. Should the consensus guidelines’ specific criteria for the diagnosis of invasive fungal infection be changed? Clin. Infect. Dis.41(Suppl. 6), S377–S380 (2005).